News & Events CTI Announces Achim Nutzenberger, MD has joined as Medical Director

CTI Announces Achim Nutzenberger, MD has joined as Medical Director

August 12, 2015

CTI Clinical Trial and Consulting Services Announces Achim Nutzenberger, MD has joined as Medical Director

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ August 12, 2015] CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces Achim Nutzenberger, MD, has joined as Medical Director, and will be based in Europe. Dr. Nutzenberger has significant experience in the clinical development of pharmaceuticals and medical devices, including marketing, sales, and pharmacovigilance, as well as over two decades of therapeutic experience in urology, ophthalmology, nephrology, and transplantation. 

“We are delighted that Achim Nutzenberger has joined CTI’s medical team,” said William Aronstein, PhD, MD, Vice President, Medical Affairs. “His experience and medical knowledge will help us support our study teams and sponsors, especially in Europe.”

Prior to joining CTI, Dr. Nutzenberger served as Head of the NephroCare Coordination Clinical Research Organization within Fresenius Medical Care, where he played a leading role in managing a network of more than 800 clinics, more than 90,000 patients and more than 20,000 employees in Europe, the Middle East, Africa, and Latin America. In this role, he was also responsible for all clinical research activities and for the set-up of medical research services, database evaluations, and feasibilities for third party pharmaceutical and device industry clients. 

Dr. Nutzenberger also worked as a part of Fresenius Biotech, and was responsible globally for clinical research, medical marketing, and sales in transplantation in addition to working in immunology and hematology.  He also contributed significantly to the clinical development and global success of Fresenius Biotech´s ATG, an important polyclonal anti-T lymphocyte immunoglobin.

Dr. Nutzenberger completed his medical studies at the Universities of Bochum and Ulm, Germany, Harvard University, and the Technical University of Munich, Germany. He completed and defended his dissertation, summa cum laude, at the Institute of Anatomy at the Ludwig-Maximilians-University, Munich. After extensive post-graduate training in surgery, urology, and radiology at university hospitals in Munich and Boston, he qualified as a specialist in Ophthalmology at the University of Frankfurt Medical School. In addition, he earned an Executive MBA from the University of St. Gallen, Switzerland.

 

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com

Original Press Release

Subscribe to our mailing list

* indicates required